SCHEMBL6403588

SCHEMBL6403588

O=C(CCCc1cccc(O)c1)c1ccc(O)cc1OP(=O)(O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HDAC6 Q9UBN7 1/20 0.43
AKR1B10 O60218 3/20 0.41
AKR1B1 P15121 3/20 0.41
MGLL Q99685 1/20 0.39
DPP4 P27487 1/20 0.37
HTT P42858 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6396603 0.93 MEN1 (0.53) MEN1KMT2AHDAC6AKR1B10AKR1B1
SCHEMBL6402197 0.90 HDAC6 (0.43) MEN1KMT2AHDAC6AKR1B10AKR1B1
SCHEMBL6404353 0.89 MEN1 (0.58) MEN1KMT2AAKR1B10AKR1B1DPP4
SCHEMBL6396414 0.85 HIF1A (0.44) MEN1KMT2AHTT
SCHEMBL6401879 0.83 CBS (0.50) MEN1KMT2AHDAC6AKR1B10AKR1B1
SCHEMBL6401793 0.82 ABCB1 (0.45) MEN1KMT2AHDAC6DRD2DRD1
SCHEMBL6395114 0.82 MGLL (0.45) HDAC6AKR1B10AKR1B1MGLLDRD2
SCHEMBL6399808 0.82 CALM1 (0.44) HDAC6AKR1B10AKR1B1MGLLDRD2
SCHEMBL6395137 0.82 ACHE (0.47) MEN1KMT2AHDAC6MGLLHTT
SCHEMBL6397688 0.81 HDAC6 (0.46) HDAC6AKR1B10AKR1B1MGLLDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885HDAC6 4653/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MEN1 2179/4885KMT2A 4828/4885HDAC6 4532/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885HDAC6 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.